The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A
- 28 February 2002
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (9) , 662-667
- https://doi.org/10.1056/nejmoa011979
Abstract
Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII.Keywords
This publication has 14 references indexed in Scilit:
- Analysis of human self-reactive antibody repertoires by quantitative immunoblottingJournal of Immunological Methods, 2000
- Monoclonal Antibody Light Chain with Prothrombinase ActivityBiochemistry, 2000
- Catalytic activity of antibodies against factor VIII in patients with hemophilia ANature Medicine, 1999
- Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII InhibitionPublished by Elsevier ,1996
- Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique.Proceedings of the National Academy of Sciences, 1995
- DNA Hydrolyzing AutoantibodiesScience, 1992
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Catalytic Hydrolysis of Vasoactive Intestinal Peptide by Human AutoantibodyScience, 1989
- Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.Journal of Clinical Investigation, 1989
- Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.Journal of Clinical Investigation, 1988